Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 17 results.
User Information
Export Records
  1. 1.   Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model
  2. Yamamoto, Jun; Murata, Takuya; Sugisawa, Norihiko; Higuchi, Takashi; Tashiro, Yoshihiko; Nishino, Hiroto; Inubushi, Sachiko; Sun, Y U; Lim, Hyein; Miyake, Kentaro; Shimoya, Koichiro; Nomura, Tsunehisa; Kurebayashi, Junichi; Tanino, Hirokazu; Hozumi, Chihiro; Bouvet, Michael; Singh,Shree Ram; Endo, Itaru; Hoffman, Robert M
  3. Anticancer research. 2020, May; 40(5): 2475-2479.
  1. 2.   A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib
  2. Yamamoto, Jun; Murata, Takuya; Tashiro, Yoshihiko; Higuchi, Takashi; Sugisawa, Norihiko; Nishino, Hiroto; Inubushi, Sachiko; Sun, Y U; Lim, Hyein; Miyake, Kentaro; Hongo, Atsushi; Nomura, Tsunehisa; Saitoh, Wataru; Moriya, Takuya; Tanino, Hirokazu; Hozumi, Chihiro; Bouvet, Michael; Singh,Shree Ram; Endo, Itaru; Hoffman, Robert M
  3. Anticancer research. 2020, May; 40(5): 2509-2514.
  1. 3.   Applications of Site-Specific Labeling to Study HAMLET, a Tumoricidal Complex of alpha-Lactalbumin and Oleic Acid
  2. Mercer, N.; Ramakrishnan, B.; Boeggeman, E.; Qasba, P. K.
  3. Plos One. 2011, Oct; 6(10): 12.
  1. 4.   The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest
  2. Nagl, N. G.; Patsialou, A.; Haines, D. S.; Dallas, P. B.; Beck, G. R.; Moran, E.
  3. Cancer Research. 2005, OCT 15; 65(20): 9236-9244.
  1. 5.   In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
  2. Hollingshead, M.; Alley, M.; Burger, A. M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H. H.; Sausville, E. A.
  3. Cancer Chemotherapy and Pharmacology. 2005, AUG; 56(2): 115-125.
  1. 6.   Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer
  2. Palmieri, D.; Halverson, D. O.; Ouatas, T.; Horak, C. E.; Salerno, M.; Johnson, J.; Figg, W. D.; Hollingshead, M.; Hursting, S.; Berrigan, D.; Steinberg, S. M.; Merino, M. J.; Steeg, P. S.
  3. Journal of the National Cancer Institute. 2005, MAY 4; 97(9): 632-642.
  1. 7.   Elucidation of thioredoxin as a molecular target for antitumor quinols
  2. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. G.
  3. Cancer Research. 2005, MAY 1; 65(9): 3911-3919.
  1. 8.   Arylthioindoles, potent inhibitors of tubulin polymerization
  2. De Martino, G.; La Regina, G.; Coluccia, A.; Edler, M. C.; Barbera, M. C.; Brancale, A.; Wilcox, E.; Hamel, E.; Artico, M.; Silvestri, R.
  3. Journal of Medicinal Chemistry. 2004, DEC 2; 47(25): 6120-6123.
  1. 9.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
  1. 10.   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models
  2. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D.
  3. Breast Cancer Research and Treatment. 2004, SEP; 87(1): 97-107.
  1. 11.   Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Mihalic, K.; Fan, Y. X.; Xiao, W. H.; Howard, O. M. Z.; Appella, E.; Maynard, A. T.; Farrar, W. L.
  3. Nature Medicine. 2004 10(1): 40-47.
  1. 12.   Synthesis, cytotoxicity, and inhibitory effects on tubulin polymerization of a new 3-heterocyclo substituted 2-styrylquinazolinones
  2. Raffa, D.; Edler, M. C.; Daidone, G.; Maggio, B.; Merickech, M.; Plescia, S.; Schillaci, D.; Bai, R. L.; Hamel, E.
  3. European Journal of Medicinal Chemistry. 2004 39(4): 299-304.
  1. 13.   Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells
  2. Loaiza-Perez, A. I.; Kenney, S.; Boswell, J.; Hollingshead, M.; Alley, M. C.; Hose, C.; Ciolino, H. P.; Yeh, G. C.; Trepel, J. B.; Vistica, D. T.; Sausville, E. A.
  3. Molecular Cancer Therapeutics. 2004 3(6): 715-725.
  1. 14.   Isolation and preliminary characterization of the human and mouse homologues of the bacterial cell cycle gene era
  2. Britton, R. A.; Chen, S. M.; Wallis, D.; Koeuth, T.; Powell, B. S.; Shaffer, L. G.; Largaespada, D.; Jenkins, N. A.; Copeland, N. G.; Court, D. L.; Lupski, J. R.
  3. Genomics. 2000 67(1): 78-82.
  1. 15.   Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30
  2. Lee-Huang, S.; Huang, P. L.; Sun, Y. T.; Chen, H. C.; Kung, H. F.; Murphy, W. J.
  3. Anticancer Research. 2000 20(2A): 653-659.
  1. 16.   The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting
  2. Cardiff, R. D.; Anver, M. R.; Gusterson, B. A.; Hennighausen, L.; Jensen, R. A.; Merino, M. J.; Rehm, S.; Russo, J.; Tavassoli, F. A.; Wakefield, L. M.; Ward, J. M.; Green, J. E.
  3. Oncogene. 2000 19(8 Special Issue SI): 968-988.
  1. 17.   Metallothionein and Apoptosis in Primary Human Hepatocellular Carcinoma and Metastatic Adenocarcinoma
  2. Deng, D. X.; Chakrabarti, S.; Waalkes, M. P.; Cherian, M. G.
  3. Histopathology. 1998 32(4): 340-347.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel